Sim So Yoon, Watts Elizabeth, Constenla Dagna, Huang Shuoning, Brenzel Logan, Patenaude Bryan N
International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Value Health. 2021 Jan;24(1):70-77. doi: 10.1016/j.jval.2020.07.010. Epub 2020 Oct 31.
Understanding the level of investment needed for the 2021-2030 decade is important as the global community faces the next strategic period for vaccines and immunization programs. To assist with this goal, we estimated the aggregate costs of immunization programs for ten vaccines in 94 low- and middle-income countries from 2011 to 2030.
We calculated vaccine, immunization delivery and stockpile costs for 94 low- and middle-income countries leveraging the latest available data sources. We conducted scenario analyses to vary assumptions about the relationship between delivery cost and coverage as well as vaccine prices for fully self-financing countries.
The total aggregate cost of immunization programs in 94 countries for 10 vaccines from 2011 to 2030 is $70.8 billion (confidence interval: $56.6-$93.3) under the base case scenario and $84.1 billion ($72.8-$102.7) under an incremental delivery cost scenario, with an increasing trend over two decades. The relative proportion of vaccine and delivery costs for pneumococcal conjugate, human papillomavirus, and rotavirus vaccines increase as more countries introduce these vaccines. Nine countries in accelerated transition phase bear the highest burden of the costs in the next decade, and uncertainty with vaccine prices for the 17 fully self-financing countries could lead to total costs that are 1.3-13.1 times higher than the base case scenario.
Resource mobilization efforts at the global and country levels will be needed to reach the level of investment needed for the coming decade. Global-level initiatives and targeted strategies for transitioning countries will help ensure the sustainability of immunization programs.
鉴于全球社会面临疫苗和免疫规划的下一个战略时期,了解2021年至2030年这十年所需的投资水平非常重要。为了助力实现这一目标,我们估算了19个低收入和中等收入国家在2011年至2030年期间十种疫苗的免疫规划总成本。
我们利用最新可得数据源,计算了94个低收入和中等收入国家的疫苗、免疫接种交付和储备成本。我们进行了情景分析,以改变关于交付成本与覆盖率之间关系以及完全自筹资金国家疫苗价格的假设。
在基本情景下,94个国家在2011年至2030年期间十种疫苗的免疫规划总费用为708亿美元(置信区间:566亿至933亿美元),在交付成本增加情景下为841亿美元(728亿至1027亿美元),在二十年里呈上升趋势。随着更多国家引入肺炎球菌结合疫苗、人乳头瘤病毒疫苗和轮状病毒疫苗,这些疫苗的疫苗和交付成本相对比例增加。九个处于加速转型阶段的国家在未来十年承担最高的成本负担,17个完全自筹资金国家的疫苗价格不确定性可能导致总成本比基本情景高出1.3至13.1倍。
需要在全球和国家层面开展资源筹集工作,以达到未来十年所需的投资水平。全球层面的举措和针对转型国家的有针对性战略将有助于确保免疫规划的可持续性。